Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Authors :: Auner, H.W. Gavriatopoulou, M. Delimpasi, S. Simonova, M. Spicka, I. Pour, L. Dimopoulos, M.A. Kriachok, I. Pylypenko, H. Leleu, X. Doronin, V. Usenko, G. Hajek, R. Benjamin, R. Dolai, T.K. Sinha, D.K. Venner, C.P. Garg, M. Stevens, D.A. Quach, H. Jagannath, S. Moreau, P. Levy, M. Badros, A. Anderson, L.D., Jr. Bahlis, N.J. Facon, T. Mateos, M.V. Cavo, M. Chai, Y. Arazy, M. Shah, J. Shacham, S. Kauffman, M.G. Richardson, P.G. Grosicki, S.
Publication Year :: 2021
Abstract: Elderly and frail patients with multiple myeloma (MM) are more vulnerable to the toxicity of combination therapies, often resulting in treatment modifications and suboptimal outcomes. The phase 3 BOSTON study showed that once-weekly selinexor and bortezomib with low-dose dexamethasone (XVd) improved PFS and ORR compared with standard twice-weekly bortezomib and moderate-dose dexamethasone (Vd) in patients with previously treated MM. This is a retrospective subgroup analysis of the multicenter, prospective, randomized BOSTON trial. Post hoc analyses were performed to compare XVd versus Vd safety and efficacy according to age and frailty status (

Tools